LONDON – Zealand Pharma A/S advanced its hopes of delivering the second once-daily glucagon-like peptide-1 agonist (GLP-1) to the market, announcing the results from a Phase III trial comparing its product lixisenatide to exenatide (Byetta), which is administered twice daily. (BioWorld International)

LONDON – Antisoma plc has taken a double hit with the failure of its only two clinical programs, as the lead product AS1413 failed in a pivotal Phase III trial in secondary acute myeloid leukemia (AML) and a Phase IIb trial of AS1411 in AML was halted after an interim analysis. (BioWorld International)